Testing TB medicines for people with drug-resistant TB and HIV
Part of Immune system & allergy, Infections clinical trials.
This trial studies a treatment plan for people who have both drug-resistant tuberculosis (TB) and HIV. It focuses on starting a specific TB medication (bedaquiline) and, if needed, HIV treatment soon after enrollment to see what approach works best.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your TB test shows TB (by culture or a molecular test).
- Your HIV test is positive (or you have a known HIV positive history).
- Your TB test shows TB is resistant to rifampicin, confirmed by a DNA test (like GeneXpert) or standard drug-sensitivity testing.
- You start a TB regimen that includes bedaquiline within 4 weeks of enrolling—and this is your first time using bedaquiline.
- You are already taking HIV treatment that includes dolutegravir, or you can start it within 4 weeks of enrolling.
- You can understand and consent in English or isiZulu.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new tuberculosis drug called TBD09 combined with other TB medicines in people with newly diagnosed, drug-sensitive TB. The goal is to see if this combination works well and is safe.
This trial tests a combination of drugs for people with active tuberculosis who have not been treated before. It aims to find a better way to treat TB, even if the bacteria are resistant to some drugs.
This study tests if bedaquiline can prevent tuberculosis (TB) in people who have been in close contact with someone with active TB, including people living with HIV. If you qualify, you would take the study medicine and be monitored to see if it prevents you from developing TB.
This trial tests a personalized treatment approach for people with rifampicin-resistant TB that is still sensitive to fluoroquinolones. It aims to find the best combination of medicines based on your specific TB profile.
This trial tests a three-drug combination (bedaquiline, delamanid, and linezolid) to see if it's safe and works well for people with multi-drug resistant or rifampicin-resistant tuberculosis. It may offer a new treatment option if standard drugs aren't working.
This trial tests a shorter course of three drugs (bedaquiline, moxifloxacin, and pyrazinamide) for people with newly diagnosed, drug-sensitive TB. It aims to see how quickly the drugs kill the bacteria in the first few days of treatment.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.